ReNerve products feature in industry forum at ASSH
Released
Released
Announcement PDF
+61 (03) 9482 3940
157 Heidelberg Rd,
Northcote, VIC 3070
www.renerve.com.au
ASX Announcement
10 October 2025
ReNerve product range to feature at American Society for Surgery of the Hand
(ASSH) event
ReNerve Limited (ASX, "ReNerve" or "the Company"), an Australian pioneering medical device company
developing innovative products for peripheral nerve injury ("PNI") repair, is pleased to announce that its product
portfolio will be the feature of an industry forum focused on nerve repair.
The American Society for Surgery of the Hand (ASSH) event in Vancouver reviews methods of nerve repair and
will illustrate the use of the various ReNerve nerve repair products including its nerve cuff, nerve conduit and
nerve guide matrix.
During ASSH, ReNerve will also be launching its complementary human tissue Empliq product ranges.
ReNerve is developing a portfolio of peripheral nerve repair and replacement products allowing surgeons to
complete a wide range of nerve repairs, from the less complicated, such as coopted severed nerves, through to
the most complex of procedures including the replacement of damaged nerves. ReNerve's unique NervAlign®
Nerve Cuff has been successfully used in a variety of surgical settings and has enjoyed strong endorsement from
leading surgeons. It is expected to be joined on the market shortly by the first of ReNerve’s nerve conduit
products.
The Company is also developing a nerve guide matrix as a room temperature stored 'ready-to-go' alternative to
nerve grafts or harvested nerve replacement. This will give ReNerve a unique position in the market with a
complete portfolio for all aspects of peripheral nerve repair, with products that are functional and convenient, all
stored at room temperature to make them practical for logistics and use.
"The event is designed to show attendees the various techniques for repairing and replacing injured peripheral
nerves. ReNerve has the competitive advantage that it is developing a comprehensive range of nerve repair
products to enable surgeons to approach any and all nerve repairs with options, to the benefit of patients, and
this industry event will highlight the benefits of our range," said ReNerve CEO Dr Julian Chick.
ReNerve is progressing the commercialisation of deep dermal and amniotic tissue-based product ranges under a
strategic partnership with Berkeley Biologics LLC announced on 2 June 2025. ReNerve is leveraging its eCOO
technology, already proven through its Nervalign® Nerve Cuff, to develop and bring to market a range of nerve
conduit products. The global market for peripheral nerve repair is estimated to be around USD$1.6Bn and
growing at 17+%. The global dermal and amniotic tissue market is estimated to be worth around USD$2.7 billion
in 2024 and growing at around 12% CAGR1
, with these products used in a range of applications.
- ENDS -
1
MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025
2 | P a g e
This announcement has been approved for release by the Company’s Board of Directors.
For further information and enquiries, please contact:
Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au
Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au
About ReNerve Limited (ASX:RNV)
ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical
technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device
company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral
nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients
worldwide.
Proven Clinical Success
ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a dramatic difference
in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable
results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores
dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant
improvement that's changing lives.
Comprehensive Product Portfolio
ReNerve is advancing a complete suite of nerve repair solutions:
• NervAlign® Nerve Cuff – Our bioabsorbable protective wrap, naturally absorbed within six months of
surgery.
• Deep Dermal tissue product -- A unique deep dermal product used in reconstructive and cosmetic surgical
cases.
• Amniotic tissue product ranges -- Three amniotic tissue product ranges used to aid the healing of wounds.
• NervAlign® Nerve Conduit Range – Next-generation nerve conduit leveraging advantages of eCOO
technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
• NervAlign® Nerve Guide Matrix – a customised and ready-to-use alternative to existing nerve grafts, for
treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to
undergo additional sural nerve harvesting.
• NervAlign® Bionic Nerve – Next-generation combination technology for the most challenging nerve
repairs.
3 | P a g e
Market Leadership and Growth
With demonstrated market traction since the Company’s 2022 product launch, ReNerve achieved 53% revenue
growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution
for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at
US$1.96 billion in 2024 and is projected to reach $6.2 billion by 2031.2
Vision and Values
We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for
nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's
natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve
surgery.
2
Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)
Share your feedback
Discover